South Korea · Delayed Price · Currency is KRW Genolution Statistics
Total Valuation
Genolution has a market cap or net worth of KRW 27.50 billion. The enterprise value is 23.32 billion.
| Market Cap | 27.50B |
| Enterprise Value | 23.32B |
Important Dates
The last earnings date was Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genolution has 18.07 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 18.07M |
| Shares Outstanding | 18.07M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 19.83% |
| Owned by Institutions (%) | n/a |
| Float | 12.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.80 |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.60 |
| EV / Sales | 2.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.28 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.30 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.42 |
| Interest Coverage | -8.85 |
Financial Efficiency
Return on equity (ROE) is -13.49% and return on invested capital (ROIC) is -11.71%.
| Return on Equity (ROE) | -13.49% |
| Return on Assets (ROA) | -4.74% |
| Return on Invested Capital (ROIC) | -11.71% |
| Return on Capital Employed (ROCE) | -10.97% |
| Weighted Average Cost of Capital (WACC) | 3.80% |
| Revenue Per Employee | 130.95M |
| Profits Per Employee | -119.57M |
| Employee Count | 75 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 2.46 |
Taxes
In the past 12 months, Genolution has paid 3.90 million in taxes.
| Income Tax | 3.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.28% in the last 52 weeks. The beta is 0.08, so Genolution's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | -40.28% |
| 50-Day Moving Average | 1,813.48 |
| 200-Day Moving Average | 2,023.53 |
| Relative Strength Index (RSI) | 23.96 |
| Average Volume (20 Days) | 64,797 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genolution had revenue of KRW 9.82 billion and -8.97 billion in losses. Loss per share was -496.20.
| Revenue | 9.82B |
| Gross Profit | 3.69B |
| Operating Income | -7.54B |
| Pretax Income | -9.89B |
| Net Income | -8.97B |
| EBITDA | -5.54B |
| EBIT | -7.54B |
| Loss Per Share | -496.20 |
Balance Sheet
The company has 27.57 billion in cash and 24.07 billion in debt, with a net cash position of 3.50 billion or 193.69 per share.
| Cash & Cash Equivalents | 27.57B |
| Total Debt | 24.07B |
| Net Cash | 3.50B |
| Net Cash Per Share | 193.69 |
| Equity (Book Value) | 68.32B |
| Book Value Per Share | 3,812.88 |
| Working Capital | 7.75B |
Cash Flow
In the last 12 months, operating cash flow was -5.07 billion and capital expenditures -373.59 million, giving a free cash flow of -5.45 billion.
| Operating Cash Flow | -5.07B |
| Capital Expenditures | -373.59M |
| Depreciation & Amortization | 2.00B |
| Net Borrowing | -325.29M |
| Free Cash Flow | -5.45B |
| FCF Per Share | -301.39 |
Margins
Gross margin is 37.58%, with operating and profit margins of -76.76% and -91.31%.
| Gross Margin | 37.58% |
| Operating Margin | -76.76% |
| Pretax Margin | -100.71% |
| Profit Margin | -91.31% |
| EBITDA Margin | -56.37% |
| EBIT Margin | -76.76% |
| FCF Margin | n/a |
Dividends & Yields
Genolution does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.07% |
| Shareholder Yield | -0.07% |
| Earnings Yield | -32.61% |
| FCF Yield | -19.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 19, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Apr 19, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Genolution has an Altman Z-Score of 1.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.51 |
| Piotroski F-Score | 3 |